Evidence map›Paper›PMID 39316442›Full record

ArticleThe Journal of clinical investigation2024

Innate immune cell activation by adjuvant AS01 in human lymph node explants is age independent.

Vicki V Stylianou, Kirstie M Bertram, Van Anh Vo, Elizabeth B Dunn, Heeva Baharlou, Darcii J Terre, James Elhindi, Elisabeth Elder, James French, Farid Meybodi and 5 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Macrophage heterogeneity in human secondary lymphoid organs.Clinical science (London, England : 1979) · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Current status of immunisation for herpes zoster.Human vaccines & immunotherapeutics · 2025
    Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vicki V StylianouCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Kirstie M BertramCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Van Anh VoCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Elizabeth B DunnCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Heeva BaharlouCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Darcii J TerreCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
James ElhindiResearch and Education Network, Western Sydney Local Health District, Westmead, New South Wales, Australia.
Elisabeth ElderSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
James FrenchSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Farid MeybodiSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Stéphane T TemmermanGSK, Rixensart, Belgium.
Arnaud M DidierlaurentCenter of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Margherita CocciaGSK, Rixensart, Belgium.
Kerrie J SandgrenCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Anthony L CunninghamCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine adjuvants are thought to work by stimulating innate immunity in the draining lymph node (LN), although this has not been proven in humans. To bridge the data obtained in animals to humans, we have developed an in situ human LN explant model to investigate how adjuvants initiate immunity. Slices of explanted LNs were exposed to vaccine adjuvants and revealed responses that were not detectable in LN cell suspensions. We used this model to compare the liposome-based AS01 with its components, monophosphoryl lipid A (MPL) and QS-21, and TLR ligands. Liposomes were predominantly taken up by subcapsular sinus-lining macrophages, monocytes, and DCs. AS01 induced DC maturation and a strong proinflammatory cytokine response in intact LN slices but not in dissociated cell cultures, in contrast to R848. This suggests that the onset of the immune response to AS01 required a coordinated activation of LN cells in time and space. Consistent with the robust immune response observed in older adults with AS01-adjuvanted vaccines, the AS01 response in human LNs was independent of age, unlike the response to R848. This human LN explant model is a valuable tool for studying the mechanism of action of adjuvants in humans and for screening new formulations to streamline vaccine development.

Indexed as

Adjuvants, ImmunologicImmunity, InnateLymph NodesAdultAgedCytokinesDendritic CellsFemaleHumansLipid ALiposomesMaleMiddle AgedAdjuvants, ImmunologicCytokinesLipid ALiposomesmonophosphoryl lipid AImmunologyInnate immunityLymphMacrophagesVaccines

Identifiers

PMID39316442
PMCPMC11563676

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.